

6-19-2020

## Single Center Study of the Impella Pump

Supraja Thunuguntla

*The University of Texas Rio Grande Valley*, [supraja.thunuguntla@utrgv.edu](mailto:supraja.thunuguntla@utrgv.edu)

Charles F. Mild

*The University of Texas Rio Grande Valley*

Follow this and additional works at: [https://scholarworks.utrgv.edu/som\\_pub](https://scholarworks.utrgv.edu/som_pub)



Part of the [Medicine and Health Sciences Commons](#)

---

### Recommended Citation

Thunuguntla, Supraja and Mild, Charles F., "Single Center Study of the Impella Pump" (2020). *School of Medicine Publications and Presentations*. 84.

[https://scholarworks.utrgv.edu/som\\_pub/84](https://scholarworks.utrgv.edu/som_pub/84)

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [justin.white@utrgv.edu](mailto:justin.white@utrgv.edu), [william.flores01@utrgv.edu](mailto:william.flores01@utrgv.edu).

## Single Center Study of the Impella Pump

Supraja Thunuguntla, Charles F. Mild

*Department of Internal Medicine at The University of Texas Rio Grande Valley, Valley Baptist Medical Center*

### Background

Impella® is a percutaneously inserted ventricular assist device. Its use increased from 11 devices placed in 2016 to 39 in 2019 at Valley Baptist Medical Center (VBMC). We review the anticoagulation options, side effects and mortality.

### Methods

We conduct a retrospective chart review of all patients placed on Impella from January 1, 2016 to March 31, 2020 admitted to VBMC. A final sample of 107 patients was collected. Descriptive statistics were used to assess the distribution of variables; continuous variables summarized as mean values with standard deviations and categorical variables summarized as counts and percentages.

### Results

The indication for Impella was protected percutaneous coronary intervention (PCI) (71%, of which 18.4% was intervention on a previous coronary artery bypass graft, CABG), cardiogenic shock (17.7%) or coronary angiogram prior to CABG (11.3%). Average duration of being placed on support was  $1.3 \pm 1.8$  days.

Periprocedural anticoagulants administered by cardiologist were heparin (H), bivalirudin (B), or both. Some patients received enoxaparin (E) [dosed as per ACS protocol] for  $\geq 24$ hrs before the procedure. Anticoagulation groups are H (55.1%), B (22.4%), H+B (7.5%), E+H (3.7%), E+B (8.4%), and none (2.8%). Observed side effects were acute bleeding (18.7%) with hemoglobin  $\leq 7$  mg/dl by group is 10.1% vs 20.8% vs 37.5% vs 50% vs 33.3 respectively ( $p=0.06$ ), femoral pseudoaneurysm (2.8%) and retroperitoneal bleed (0.9%). Average aPTT was 70-140 seconds in the heparin group, ACT (measured in 9.3% of patients only) was  $275 \pm 212.4$ , fibrinogen (measured in 12.1% of patients only) was  $356 \pm 125.8$ .

Death within a month (32/107) occurred when indication was cardiogenic shock (83.3%) versus protected PCI (28.9%) ( $p=0.00018$ ).

### Conclusion

In agreeance with the manufacturer's recommendation, the lowest risk of bleeding is observed with heparin (dosing: weight-based) only. Further clinical studies required for having a standardized protocol for anticoagulation with dosing and duration of therapy.

